Drug-class overview:@0.657199:0.039086:0.902803:0.039086:0.902803:0.019651:0.657199:0.019651:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
43:@0.950592:0.038665:0.976698:0.038665:0.976698:0.018632:0.950592:0.018632:0.000000:0.000000
Drug-class overview:@0.981851:0.292741:0.981851:0.109337:0.953582:0.109337:0.953582:0.292741:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
MIMS ConCISe GuIde to CardIovaSCular, MetabolIC and endoCrIne dISeaSeS :@0.216640:0.974259:0.820834:0.974259:0.820834:0.960936:0.216640:0.960936:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 :@0.820834:0.974259:0.824580:0.974259:0.824580:0.960936:0.820834:0.960936:0.000000
VOLUME 1:@0.824751:0.974259:0.906065:0.974259:0.906065:0.959690:0.824751:0.959690:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.096970:0.096324:0.105783:0.096324:0.105783:0.081640:0.096970:0.081640:0.000000
 Circulatory relapse   Pregnancy and lactation  :@0.105783:0.096840:0.479970:0.096840:0.479970:0.081852:0.105783:0.081852:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.266418:0.096324:0.275231:0.096324:0.275231:0.081640:0.266418:0.081640:0.000000
:@0.096970:0.112067:0.105783:0.112067:0.105783:0.097383:0.096970:0.097383:0.000000
 Children:@0.105783:0.112583:0.174959:0.112583:0.174959:0.097594:0.105783:0.097594:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Side effects::@0.096970:0.132784:0.200186:0.132784:0.200186:0.116393:0.096970:0.116393:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
11:@0.200184:0.127006:0.212637:0.127006:0.212637:0.117450:0.200184:0.117450:0.000000:0.000000
GI disturbances   dizziness :@0.096970:0.148535:0.309386:0.148535:0.309386:0.133546:0.096970:0.133546:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.221391:0.148019:0.230204:0.148019:0.230204:0.133335:0.221391:0.133335:0.000000
:@0.310137:0.148019:0.318950:0.148019:0.318950:0.133335:0.310137:0.133335:0.000000
 Headache • Myalgia :@0.318950:0.148535:0.479970:0.148535:0.479970:0.133546:0.318950:0.133546:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.096970:0.163762:0.105783:0.163762:0.105783:0.149077:0.096970:0.149077:0.000000
 Hypotension   Hot flushes    tachycardia :@0.105783:0.164278:0.479990:0.164278:0.479990:0.149289:0.105783:0.149289:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.232359:0.163762:0.241172:0.163762:0.241172:0.149077:0.232359:0.149077:0.000000
:@0.364439:0.163762:0.373252:0.163762:0.373252:0.149077:0.364439:0.149077:0.000000
 :@0.475776:0.164278:0.479990:0.164278:0.479990:0.149289:0.475776:0.149289:0.000000
:@0.096989:0.179504:0.105802:0.179504:0.105802:0.164820:0.096989:0.164820:0.000000
 Worsening of coronary heart disease or angina :@0.105802:0.180020:0.480028:0.180020:0.480028:0.165032:0.105802:0.165032:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
symptoms   Hypersensitivity reactions, including :@0.096989:0.195763:0.479990:0.195763:0.479990:0.180774:0.096989:0.180774:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.183387:0.195247:0.192200:0.195247:0.192200:0.180563:0.183387:0.180563:0.000000
severe  bronchospasm :@0.096989:0.211506:0.281485:0.211506:0.281485:0.196517:0.096989:0.196517:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.293050:0.210990:0.301863:0.210990:0.301863:0.196306:0.293050:0.196306:0.000000
  Increased  bleeding :@0.301863:0.211506:0.479990:0.211506:0.479990:0.196517:0.301863:0.196517:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
during  or after  surgery    thrombocytopenia :@0.097008:0.227249:0.480028:0.227249:0.480028:0.212260:0.097008:0.212260:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.307116:0.226733:0.315929:0.226733:0.315929:0.212048:0.307116:0.212048:0.000000
 :@0.475814:0.227249:0.480028:0.227249:0.480028:0.212260:0.475814:0.212260:0.000000
:@0.097027:0.242475:0.105840:0.242475:0.105840:0.227791:0.097027:0.227791:0.000000
 Incorporated into gallstones:@0.105840:0.242991:0.326512:0.242991:0.326512:0.228003:0.105840:0.228003:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Special precautions::@0.097027:0.263338:0.269458:0.263338:0.269458:0.246947:0.097027:0.246947:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
11:@0.269398:0.257571:0.281851:0.257571:0.281851:0.248015:0.269398:0.248015:0.000000:0.000000
Severe coronary arterial disease   Subvalvular :@0.096970:0.279100:0.479970:0.279100:0.479970:0.264112:0.096970:0.264112:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.368345:0.278584:0.377158:0.278584:0.377158:0.263900:0.368345:0.263900:0.000000
aortic stenosis :@0.096970:0.294843:0.223854:0.294843:0.223854:0.279854:0.096970:0.279854:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.240018:0.294327:0.248831:0.294327:0.248831:0.279643:0.240018:0.279643:0.000000
  left ventricular  outflow :@0.248638:0.294843:0.479990:0.294843:0.479990:0.279854:0.248638:0.279854:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
obstruction   Haemodynamic instability    no :@0.096989:0.310586:0.480009:0.310586:0.480009:0.295597:0.096989:0.295597:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.196164:0.310070:0.204977:0.310070:0.204977:0.295386:0.196164:0.295386:0.000000
:@0.432769:0.310070:0.441582:0.310070:0.441582:0.295386:0.432769:0.295386:0.000000
additional Iv administration with oral therapy :@0.097008:0.326329:0.480028:0.326329:0.480028:0.311340:0.097008:0.311340:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.097008:0.341555:0.105821:0.341555:0.105821:0.326871:0.097008:0.326871:0.000000
 Myasthenia gravis   Coagulation disorders :@0.105629:0.342071:0.480009:0.342071:0.480009:0.327083:0.105629:0.327083:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.278291:0.341555:0.287104:0.341555:0.287104:0.326871:0.278291:0.326871:0.000000
 :@0.475795:0.342071:0.480009:0.342071:0.480009:0.327083:0.475795:0.327083:0.000000
:@0.097008:0.357298:0.105821:0.357298:0.105821:0.342614:0.097008:0.342614:0.000000
 Concomitant anticoagulant or acetylsalicylic acid:@0.105629:0.357814:0.475737:0.357814:0.475737:0.342825:0.105629:0.342825:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Drug interactions::@0.097008:0.378015:0.251967:0.378015:0.251967:0.361624:0.097008:0.361624:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
11:@0.251927:0.372245:0.264379:0.372245:0.264379:0.362689:0.251927:0.362689:0.000000:0.000000
Increased plasma level and Cv-effects of :@0.096970:0.393774:0.479971:0.393774:0.479971:0.378785:0.096970:0.378785:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
adenosine   acetylsalicylic acid effects on platelet :@0.096970:0.409517:0.479971:0.409517:0.479971:0.394528:0.096970:0.394528:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.180770:0.409001:0.189583:0.409001:0.189583:0.394316:0.180770:0.394316:0.000000
behaviour additive   May increase hypotensive :@0.096970:0.425259:0.479951:0.425259:0.479951:0.410271:0.096970:0.410271:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.252852:0.424743:0.261665:0.424743:0.261665:0.410059:0.252852:0.410059:0.000000
effects of blood-pressure-lowering medication :@0.096970:0.441002:0.479971:0.441002:0.479971:0.426013:0.096970:0.426013:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
:@0.096970:0.456229:0.105783:0.456229:0.105783:0.441544:0.096970:0.441544:0.000000
 May counteract anticholinesterase effects of :@0.105783:0.456745:0.480009:0.456745:0.480009:0.441756:0.105783:0.441756:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
cholinesterase inhibitors:@0.096970:0.472487:0.283563:0.472487:0.283563:0.457499:0.096970:0.457499:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
REfEREnCES:@0.097162:0.503973:0.209807:0.503973:0.209807:0.487582:0.097162:0.487582:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
1.   brass  l. In the shadow of the thrombus. :@0.096970:0.518041:0.426913:0.518041:0.426913:0.504718:0.096970:0.504718:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Nature :@0.431001:0.518041:0.478790:0.518041:0.478790:0.504953:0.431001:0.504953:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Medicine.:@0.127279:0.532458:0.189128:0.532458:0.189128:0.519370:0.127279:0.519370:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 2009;15(6):607.:@0.189128:0.532458:0.294337:0.532458:0.294337:0.519135:0.189128:0.519135:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2.   nurden  at,  Poujol  C,  durrieu-Jais  C,  nurden  P. :@0.096970:0.546875:0.479492:0.546875:0.479492:0.533552:0.096970:0.533552:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Platelet glycoprotein IIb/IIIa inhibitors. :@0.127262:0.561292:0.380098:0.561292:0.380098:0.547969:0.127262:0.547969:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Arteriosclerosis, :@0.381928:0.561292:0.478842:0.561292:0.478842:0.548204:0.381928:0.548204:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Thrombosis, and Vascular Biology. :@0.127262:0.575709:0.338654:0.575709:0.338654:0.562621:0.127262:0.562621:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
1999;19(12):2835-40.:@0.338312:0.575709:0.471760:0.575709:0.471760:0.562385:0.338312:0.562385:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
3.   rožman P,  bolta Z.  use of platelet growth factors :@0.096953:0.590125:0.479509:0.590125:0.479509:0.576802:0.096953:0.576802:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
in treating wounds and soft tissue injuries. :@0.127262:0.604542:0.441879:0.604542:0.441879:0.591219:0.127262:0.591219:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Acta :@0.445967:0.604542:0.478790:0.604542:0.478790:0.591454:0.445967:0.591454:0.000000:0.000000:0.000000:0.000000:0.000000
Dermatoven.:@0.127262:0.618959:0.212202:0.618959:0.212202:0.605871:0.127262:0.605871:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 2007;16(4):156-65.:@0.212202:0.618959:0.339202:0.618959:0.339202:0.605636:0.212202:0.605636:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
4.   Fletcher  b  tK. Prasugrel as antiplatelet therapy :@0.096953:0.633376:0.479475:0.633376:0.479475:0.620053:0.096953:0.620053:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
in  patients  with  acute  coronary  syndromes  or :@0.127262:0.647793:0.479440:0.647793:0.479440:0.634470:0.127262:0.634470:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
undergoing percutaneous coronary intervention. :@0.127262:0.662210:0.479492:0.662210:0.479492:0.648886:0.127262:0.648886:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Critical Care Nurse:@0.127262:0.676627:0.245401:0.676627:0.245401:0.663539:0.127262:0.663539:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 [serial online]. 2010;30(5):46-54.:@0.245401:0.676627:0.461327:0.676627:0.461327:0.663303:0.245401:0.663303:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
5.   eppley  bl, Pietrzak  WS,  blanton M. Platelet-rich :@0.096953:0.691043:0.479492:0.691043:0.479492:0.677720:0.096953:0.677720:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
plasma:  a review of biology and applications :@0.127262:0.705460:0.479475:0.705460:0.479475:0.692137:0.127262:0.692137:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
in plastic surgery. :@0.127262:0.719877:0.273863:0.719877:0.273863:0.706554:0.127262:0.706554:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Plastic  and Reconstructive :@0.286606:0.719877:0.478807:0.719877:0.478807:0.706789:0.286606:0.706789:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Surgery.:@0.127262:0.734294:0.178609:0.734294:0.178609:0.721206:0.127262:0.721206:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2006;118(6):147e-59e:@0.214990:0.734294:0.360651:0.734294:0.360651:0.720971:0.214990:0.720971:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
10.1097/01.:@0.397032:0.734294:0.475763:0.734294:0.475763:0.720971:0.397032:0.720971:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
prs.0000239606.92676.cf.:@0.127262:0.748711:0.296646:0.748711:0.296646:0.735388:0.127262:0.735388:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
6.   everts PaM, Knape Jta,  Weibrich G, Schonberger :@0.096953:0.763128:0.479492:0.763128:0.479492:0.749804:0.096953:0.749804:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
JPaM, Hoffmann JJHl, overdevest eP, :@0.127262:0.777545:0.387590:0.777545:0.387590:0.764221:0.127262:0.764221:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
et al.:@0.388890:0.777545:0.420174:0.777545:0.420174:0.764456:0.388890:0.764456:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 Platelet :@0.420174:0.777545:0.479492:0.777545:0.479492:0.764221:0.420174:0.764221:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
rich plasma and platelet gel: a review. :@0.127262:0.791961:0.385247:0.791961:0.385247:0.778638:0.127262:0.778638:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
The Journal of :@0.384853:0.791961:0.478876:0.791961:0.478876:0.778873:0.384853:0.778873:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Extra-corporeal Technology.:@0.127262:0.806378:0.307730:0.806378:0.307730:0.793290:0.127262:0.793290:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 2006;38:174-87.:@0.307730:0.806378:0.417317:0.806378:0.417317:0.793055:0.307730:0.793055:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
7.   Marguerie Ga,  thomas-Maison  n, Ginsberg MH, :@0.096953:0.820795:0.479492:0.820795:0.479492:0.807472:0.096953:0.807472:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Plow  eF.  the  platelet  fibrinogen  interaction: :@0.127262:0.835212:0.479457:0.835212:0.479457:0.821889:0.127262:0.821889:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
evidence for proximity of the aa chain of fibrinogen :@0.127244:0.849629:0.479457:0.849629:0.479457:0.836306:0.127244:0.836306:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
to platelet membrane glycoproteins IIb/III. :@0.127244:0.864046:0.445300:0.864046:0.445300:0.850722:0.127244:0.850722:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
The :@0.452227:0.864046:0.478842:0.864046:0.478842:0.850958:0.452227:0.850958:0.000000:0.000000:0.000000:0.000000
European Journal of Biochemistry.:@0.127244:0.878462:0.347189:0.878462:0.347189:0.865374:0.127244:0.865374:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 1984;139:5-11.:@0.347189:0.878462:0.448430:0.878462:0.448430:0.865139:0.347189:0.865139:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
8.   Wong S, appleberg M, Ward CM, lewis dr. aspirin :@0.096936:0.892879:0.479475:0.892879:0.479475:0.879556:0.096936:0.879556:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
resistance in cardiovascular disease:  a  review. :@0.127244:0.907296:0.479475:0.907296:0.479475:0.893973:0.127244:0.893973:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
European Journal of Vascular and Endovascular :@0.127244:0.921713:0.478825:0.921713:0.478825:0.908625:0.127244:0.908625:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Surgery. :@0.127244:0.936130:0.181671:0.936130:0.181671:0.923042:0.127244:0.923042:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2004;27(5):456-65.:@0.181671:0.936130:0.304925:0.936130:0.304925:0.922807:0.181671:0.922807:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
9.   Horwitz Pa, Gudmundsson H.  acute coronary :@0.524220:0.094955:0.906759:0.094955:0.906759:0.081632:0.524220:0.081632:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
syndromes:@0.554528:0.109419:0.629548:0.109419:0.629548:0.096095:0.554528:0.096095:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
. :@0.629548:0.109419:0.636270:0.109419:0.636270:0.095272:0.629548:0.095272:0.000000:0.000000
ACCP Critical Care Medicine Board :@0.645729:0.109419:0.906074:0.109419:0.906074:0.096331:0.645729:0.096331:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Review.:@0.554528:0.123883:0.602558:0.123883:0.602558:0.110795:0.554528:0.110795:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 21st ed. 75-90.:@0.602558:0.123883:0.704003:0.123883:0.704003:0.110559:0.602558:0.110559:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
10.   Santilli F,  rocca  b,  de Cristofaro  r,  lattanzio S, :@0.524220:0.138347:0.906759:0.138347:0.906759:0.125023:0.524220:0.125023:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Pietrangelo l, Habib a:@0.554528:0.152810:0.702686:0.152810:0.702686:0.139487:0.554528:0.139487:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
, :@0.702686:0.152810:0.709408:0.152810:0.709408:0.138664:0.702686:0.138664:0.000000:0.000000
et al. :@0.708741:0.152810:0.741377:0.152810:0.741377:0.139722:0.708741:0.139722:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Platelet cyclooxygenase :@0.740709:0.152810:0.906759:0.152810:0.906759:0.139487:0.740709:0.139487:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
inhibition by low-dose aspirin is not reflected :@0.554528:0.167274:0.906724:0.167274:0.906724:0.153951:0.554528:0.153951:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
consistently by platelet function assays: Implications :@0.554528:0.181738:0.906724:0.181738:0.906724:0.168415:0.554528:0.168415:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
for  aspirin “resistance”. :@0.554528:0.196202:0.720954:0.196202:0.720954:0.182879:0.554528:0.182879:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Journal of the American :@0.728753:0.196202:0.906109:0.196202:0.906109:0.183114:0.728753:0.183114:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
College of Cardiology. :@0.554528:0.210666:0.697658:0.210666:0.697658:0.197578:0.554528:0.197578:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2009;53(8):667-77.:@0.697658:0.210666:0.820912:0.210666:0.820912:0.197343:0.697658:0.197343:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
11.   Snyman Jr, ed. Platelet aggregation inhibitors. :@0.524220:0.225130:0.906741:0.225130:0.906741:0.211807:0.524220:0.211807:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Monthly Index of Medical Specialities:@0.554528:0.239594:0.784941:0.239594:0.784941:0.226506:0.554528:0.226506:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
. 2011;51(8):162-5.:@0.784770:0.239594:0.903047:0.239594:0.903047:0.226270:0.784770:0.226270:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
12.   Small dS, Payne Cd, Kothare P, Yuen e, natanegara :@0.524220:0.254058:0.906741:0.254058:0.906741:0.240734:0.524220:0.240734:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
F,  teng  loh M, :@0.554528:0.268521:0.675987:0.268521:0.675987:0.255198:0.554528:0.255198:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
et al.:@0.683495:0.268521:0.719893:0.268521:0.719893:0.255433:0.683495:0.255433:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 Pharmacodynamics and :@0.719893:0.268521:0.906793:0.268521:0.906793:0.255198:0.719893:0.255198:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
pharmacokinetics of single doses of prasugrel 30 :@0.554546:0.282985:0.906793:0.282985:0.906793:0.269662:0.554546:0.269662:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
mg and clopidogrel 300 mg in healthy Chinese :@0.554546:0.297449:0.906793:0.297449:0.906793:0.284126:0.554546:0.284126:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
and white volunteers:  an open-label trial. :@0.554546:0.311913:0.852538:0.311913:0.852538:0.298590:0.554546:0.298590:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Clinical :@0.855480:0.311913:0.906126:0.311913:0.906126:0.298825:0.855480:0.298825:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Therapeutics. :@0.554546:0.326377:0.643300:0.326377:0.643300:0.313289:0.554546:0.313289:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2010;32(2):365-79.:@0.643300:0.326377:0.766554:0.326377:0.766554:0.313054:0.643300:0.313054:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
13.   Snyman Jr, ed.  anticoagulants. :@0.524237:0.340841:0.782307:0.340841:0.782307:0.327518:0.524237:0.327518:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Monthly Index of :@0.786823:0.340841:0.906109:0.340841:0.906109:0.327753:0.786823:0.327753:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Medical Specialities. :@0.554546:0.355305:0.686147:0.355305:0.686147:0.342217:0.554546:0.342217:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2011;51(8):158-61.:@0.686147:0.355305:0.809401:0.355305:0.809401:0.341982:0.686147:0.341982:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
14.   Hanna eb, rao Sv, Manoukian Sv, Saucedo JF. the :@0.524237:0.369769:0.906776:0.369769:0.906776:0.356445:0.524237:0.356445:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
evolving role of glycoprotein IIb/IIIa inhibitors in :@0.554546:0.384233:0.906741:0.384233:0.906741:0.370909:0.554546:0.370909:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
the setting of percutaneous coronary intervention: :@0.554546:0.398696:0.906793:0.398696:0.906793:0.385373:0.554546:0.385373:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Strategies to minimize bleeding risk and optimize :@0.554546:0.413160:0.906793:0.413160:0.906793:0.399837:0.554546:0.399837:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
outcomes. :@0.554546:0.427624:0.629856:0.427624:0.629856:0.414301:0.554546:0.414301:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
JACC:  Cardiovascular  Interventions.:@0.647320:0.427624:0.903013:0.427624:0.903013:0.414536:0.647320:0.414536:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 :@0.903013:0.427624:0.906759:0.427624:0.906759:0.414301:0.903013:0.414301:0.000000
2010;3(12):1209-19.:@0.554546:0.442088:0.686147:0.442088:0.686147:0.428765:0.554546:0.428765:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
15.   Chakrabarti S, Freedman Je.  dipyridamole, :@0.524237:0.456552:0.906759:0.456552:0.906759:0.443229:0.524237:0.443229:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
cerebrovascular disease, and the vasculature. :@0.554546:0.471016:0.906776:0.471016:0.906776:0.457693:0.554546:0.457693:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Vascular Pharmacology.:@0.554546:0.485480:0.711068:0.485480:0.711068:0.472392:0.554546:0.472392:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
 2008;48(4-6):143-9.:@0.711068:0.485480:0.843165:0.485480:0.843165:0.472157:0.711068:0.472157:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
16.   Kim H-H,  liao JK.  translational therapeutics of :@0.524237:0.499944:0.906793:0.499944:0.906793:0.486620:0.524237:0.486620:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
dipyridamole. :@0.554546:0.514408:0.651698:0.514408:0.651698:0.501084:0.554546:0.501084:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Arteriosclerosis, Thrombosis, and :@0.667280:0.514408:0.906126:0.514408:0.906126:0.501320:0.667280:0.501320:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Vascular Biology. :@0.554546:0.528871:0.666391:0.528871:0.666391:0.515783:0.554546:0.515783:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
2008;28(3):s39-s42.:@0.666391:0.528871:0.794058:0.528871:0.794058:0.515548:0.666391:0.515548:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
MetaBoliC Diseases:@0.524541:0.563064:0.816743:0.563064:0.816743:0.537917:0.524541:0.537917:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
anti-DiaBetiC agents:@0.524498:0.594287:0.795226:0.594287:0.795226:0.572733:0.524498:0.572733:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
In type 2 diabetes mellitus, the actions and :@0.524242:0.608968:0.907243:0.608968:0.907243:0.593980:0.524242:0.593980:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
secretions of insulin are impaired, and early :@0.524242:0.624751:0.907223:0.624751:0.907223:0.609762:0.524242:0.609762:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
stages of insulin resistance can be managed :@0.524242:0.640533:0.907281:0.640533:0.907281:0.625544:0.524242:0.625544:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
with lifestyle modifications and oral anti-diabetic :@0.524242:0.656315:0.907281:0.656315:0.907281:0.641327:0.524242:0.641327:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
drugs.  If lifestyle  modifications  fail  to control :@0.524242:0.672098:0.907223:0.672098:0.907223:0.657109:0.524242:0.657109:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
blood-glucose  levels,  patients  are  placed  on :@0.524242:0.687880:0.907204:0.687880:0.907204:0.672892:0.524242:0.672892:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
monotherapy oral anti-diabetic drugs. However, :@0.524242:0.703663:0.907243:0.703663:0.907243:0.688674:0.524242:0.688674:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
as the disease progresses, monotherapy may :@0.524242:0.719445:0.907281:0.719445:0.907281:0.704456:0.524242:0.704456:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
become inadequate and a combination of anti-:@0.524242:0.735227:0.903009:0.735227:0.903009:0.720239:0.524242:0.720239:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
diabetic drugs is required.  Further progression :@0.524242:0.751010:0.907226:0.751017:0.907226:0.736028:0.524242:0.736021:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
1-3:@0.729162:0.745233:0.743454:0.745233:0.743454:0.736494:0.729162:0.736494:0.000000:0.000000:0.000000
of the disease may lead to the failure of insulin :@0.524244:0.766799:0.907187:0.766799:0.907187:0.751811:0.524244:0.751811:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
secretion by the β-pancreatic cell as these cells :@0.524244:0.782582:0.907283:0.782582:0.907283:0.767593:0.524244:0.767593:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
are lost and patients may require insulin therapy. :@0.524244:0.798364:0.907283:0.798364:0.907283:0.783376:0.524244:0.783376:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
the loss in cells leads to a reduction in the “incretin :@0.524244:0.814147:0.907168:0.814147:0.907168:0.799158:0.524244:0.799158:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
effect”, which upregulates insulin secretion after :@0.524244:0.829929:0.907264:0.829929:0.907264:0.814940:0.524244:0.814940:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
oral ingestion of glucose.   :@0.524244:0.845711:0.737299:0.845716:0.737299:0.830728:0.524244:0.830723:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
1,2:@0.715970:0.839932:0.728871:0.839932:0.728871:0.831194:0.715970:0.831194:0.000000:0.000000:0.000000
insulins:@0.524242:0.874610:0.609678:0.874610:0.609678:0.853055:0.524242:0.853055:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
Several types of insulins are available.  these :@0.524242:0.889291:0.907243:0.889291:0.907243:0.874302:0.524242:0.874302:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
include human insulin, rapid-acting insulin :@0.524242:0.905073:0.907262:0.905073:0.907262:0.890085:0.524242:0.890085:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
analogues, neutral protamine hagedorn insulin :@0.524242:0.920856:0.907243:0.920856:0.907243:0.905867:0.524242:0.905867:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000
(nPH) and long-acting insulin. these insulins vary :@0.524242:0.936638:0.907262:0.936638:0.907262:0.921650:0.524242:0.921650:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000